Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.
Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero G.
Takahashi K, et al.
Leukemia. 2013 Oct;27(10):2081-3. doi: 10.1038/leu.2013.165. Epub 2013 Jun 7.
Leukemia. 2013.
PMID: 23774633
No abstract available.